DK1831247T3 - Hetero-oligomere HIV-kappeproteiner - Google Patents

Hetero-oligomere HIV-kappeproteiner

Info

Publication number
DK1831247T3
DK1831247T3 DK05855755T DK05855755T DK1831247T3 DK 1831247 T3 DK1831247 T3 DK 1831247T3 DK 05855755 T DK05855755 T DK 05855755T DK 05855755 T DK05855755 T DK 05855755T DK 1831247 T3 DK1831247 T3 DK 1831247T3
Authority
DK
Denmark
Prior art keywords
hiv
different
heterotrimer
env glycoprotein
hiv envelope
Prior art date
Application number
DK05855755T
Other languages
Danish (da)
English (en)
Inventor
Leonidas Stamatatos
Original Assignee
Seattle Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Biomedical Res Inst filed Critical Seattle Biomedical Res Inst
Application granted granted Critical
Publication of DK1831247T3 publication Critical patent/DK1831247T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05855755T 2004-12-29 2005-12-28 Hetero-oligomere HIV-kappeproteiner DK1831247T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032904P 2004-12-29 2004-12-29
PCT/US2005/047244 WO2006071933A2 (en) 2004-12-29 2005-12-28 Hetero-oligomeric hiv envelope proteins

Publications (1)

Publication Number Publication Date
DK1831247T3 true DK1831247T3 (da) 2009-10-12

Family

ID=36615506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05855755T DK1831247T3 (da) 2004-12-29 2005-12-28 Hetero-oligomere HIV-kappeproteiner

Country Status (9)

Country Link
US (1) US20080248063A1 (de)
EP (2) EP2088155A1 (de)
CN (1) CN101094862A (de)
AT (1) ATE435234T1 (de)
DE (1) DE602005015256D1 (de)
DK (1) DK1831247T3 (de)
ES (1) ES2328507T3 (de)
WO (1) WO2006071933A2 (de)
ZA (1) ZA200706186B (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL46110C (de) 1936-08-07 1939-02-15
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6716429B1 (en) * 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
ES2288886T3 (es) 1999-12-30 2008-02-01 Dana-Farber Cancer Institute, Inc. Proteoliposomas que contienen una proteina integral de membrana que tiene uno o mas dominios transmembrana.
CA2459426A1 (en) * 2001-09-06 2003-03-20 Progenics Pharmaceuticals, Inc. Human immunodeficiency virus envelope glycoprotein mutants and uses thereof

Also Published As

Publication number Publication date
WO2006071933A2 (en) 2006-07-06
US20080248063A1 (en) 2008-10-09
ES2328507T3 (es) 2009-11-13
CN101094862A (zh) 2007-12-26
ZA200706186B (en) 2008-06-25
EP1831247B1 (de) 2009-07-01
ATE435234T1 (de) 2009-07-15
WO2006071933A3 (en) 2007-02-15
HK1107998A1 (en) 2008-04-25
EP1831247A2 (de) 2007-09-12
DE602005015256D1 (de) 2009-08-13
EP2088155A1 (de) 2009-08-12

Similar Documents

Publication Publication Date Title
Yang et al. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
DK1402015T3 (da) Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD
JP2019501882A5 (de)
BRPI0514108A (pt) polipeptìdeo, processo para purificar o mesmo, composição, polinucleotìdeo ou polinucleotìdeos
WO2008063331A3 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
ATE308558T1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
NO991078D0 (no) HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
JP2010521147A5 (de)
JP2017501986A5 (ja) 二重特異性ｈｉｖ−１中和抗体
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
NO20025153L (no) Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
Pinón et al. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
ATE435234T1 (de) Hetero-oligomere hiv-hüllproteine
WO2005110492A3 (en) Method of using adenoviral vectors to induce an immune response
JP2006503849A5 (de)
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
ATE531809T1 (de) Neues simianes t-zell-lymphotropes virus
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
Ecker et al. Overexpression and purification of a recombinant chimeric HIV type 2/HIV type 1 envelope peptide and application in an accelerated immunobased HIV type 1/2 antibody detection system (AIBS): a new rapid serological screening assay
Bianchi et al. Covalent Trimeric Coiled Coils of the HIV gp41 HR1 Region are Extremely Potent and Broadly Neutralizing Inhibitors of Viral Infection